Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10918882 | Radiotherapy and Oncology | 2012 | 6 Pages |
Abstract
EBRT + HDR-BTb resulted in a significant improvement in RFS compared to EBRT alone with a 31% reduction in the risk of recurrence (p = 0.01) and similar incidence of severe late urinary and rectal morbidity.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Peter J. Hoskin, Ana M. Rojas, Peter J. Bownes, Gerry J. Lowe, Peter J. Ostler, Linda Bryant,